Soluble markers of viral rebound and post-treatment HIV control.

Autor: Giron LB; Northwestern University, Chicago, Illinois, USA., Pasternak AO; Amsterdam UMC, University of Amsterdam, Laboratory of Experimental Virology, Department of Medical Microbiology and Infection Prevention, Amsterdam, Netherlands., Abdel-Mohsen M; Northwestern University, Chicago, Illinois, USA.
Jazyk: angličtina
Zdroj: Current opinion in HIV and AIDS [Curr Opin HIV AIDS] 2024 Sep 26. Date of Electronic Publication: 2024 Sep 26.
DOI: 10.1097/COH.0000000000000889
Abstrakt: Purpose of Review: We focus on the different classes of biological molecules measurable in easily accessible bodily fluids that have the potential to serve as biomarkers for the HIV post-treatment controller (PTC) phenotype and/or the timing of viral rebound after stopping antiretroviral therapy (ART).
Recent Findings: Various viral components and host factors measurable in body fluids can play crucial roles in understanding and predicting the PTC phenotype. We review recent findings linking viral components, the quantitative and qualitative features of antibodies (including autologous HIV-specific antibodies), markers of inflammation and tissue damage, other host proteins (including hormones such as sex hormones), as well as metabolites, extracellular vesicles, and cell-free DNA to HIV control post-ART interruption. Several of these molecules can or have the potential to predict the time and probability of viral rebound after stopping ART and are biologically active molecules that can directly or indirectly (by modulating immune pressures) impact the size and activity of HIV reservoirs during and post-ART interruption.
Summary: A comprehensive model combining multiple markers is needed to predict the PTC phenotype. This model can be leveraged to predict and understand the PTC phenotype, which can guide novel curative interventions to replicate this phenotype in post-treatment non-controllers.
(Copyright © 2024 Wolters Kluwer Health, Inc. All rights reserved.)
Databáze: MEDLINE